Astria Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To adopt the Agreement and Plan of Merger, dated as of October 14, 2025 by and among BioCryst Pharmaceuticals, Inc. ("BioCryst"), Axel Merger Sub, Inc., a wholly owned subsidiary of BioCryst ("Merger Sub"), and Astria Therapeutics, Inc. ("Astria"), under which Merger Sub will merge with and into Astria, with Astria surviving and becoming a wholly owned subsidiary of BioCryst (the "Merger") (the "Merger Proposal").

The 36 asset managers below reported 4,494,368 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: To adopt the Agreement and Plan of Merger, dated as of October 14, 2025 by and among BioCryst Pharmaceuticals, Inc. (''BioCryst''), Axel Merger Sub, Inc., a wholly owned subsidiary of BioCryst (''Merger Sub''), and Astia Therapeutics, Inc. (''Astia''), under which Merger Sub will merge with and into Astia, with Astia surviving and becoming a wholly owned subsidiary of BioCryst (the ''Merger'') (the ''Merger Proposal'').

The 11 asset managers below reported 2,540,337 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: TO APPROVE ONE OR MORE ADJOURNMENTS OF THE SPECIAL MEETING TO A LATER DATE OR DATES IF THERE ARE NOT SUFFICIENT VOTES FOR ADOPTION OF THE MERGER PROPOSAL ON THE DATE ON WHICH THE SPECIAL MEETING IS HELD.

The 47 asset managers below reported 6,990,168 for, 40,211 against, 4,530 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To cast a vote, on a non-binding, advisory basis, to approve the Merger-related named executive officer compensation as disclosed in the table entitled "Golden Parachute Compensation" and its accompanying footnotes which is included in the section of the proxy statement entitled "The Merger- Interests of Astria's Directors and Executive Officers in the Merger," as required by Section 14A of the Securities Exchange Act of 1934, as amended, which was enacted as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.

Astria Therapeutics, Inc.’s own tally for this item (“Compensation Proposal At the Special Meeting, the Company's stockholders also voted upon and approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation as disclosed in the table e”): 33,236,762 for, 2,035,104 against — passed, per its Form 8-K filed January 21, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Compensation Proposal At the Special Meeting, the Company's stockholders also voted upon and approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation as disclosed in the table entitled "Golden Para”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 47 managers: 6,816,653 for, 213,726 against, 4,530 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 120 managers: 24,514,109 for, 1,976,191 against, 406,076 abstained, 123 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Advisory Vote on Golden Parachutes

Astria Therapeutics, Inc.’s own tally for this item (“Compensation Proposal At the Special Meeting, the Company's stockholders also voted upon and approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation as disclosed in the table e”): 33,236,762 for, 2,035,104 against — passed, per its Form 8-K filed January 21, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Compensation Proposal At the Special Meeting, the Company's stockholders also voted upon and approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation as disclosed in the table entitled "Golden Para”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 2 asset managers below reported 482,726 for.